WASHINGTON, D.C., November 24, 2020 - Baker Botts L.L.P. announced today that its client Merck & Co., Inc. (NYSE:MRK) has entered into a definitive agreement to acquire all outstanding shares of OncoImmune for $425 million in cash.
With the acquisition of Oncolmmune, a privately-held clinical-stage biopharmaceutical company, Merck will expand its range of clinical programs in response to COVID-19. Merck’s press release can be found here.
The Baker Botts team, which provided antitrust counsel for Merck on the transaction, was led by Antitrust Practice Co-Chair Stephen Weissman, Special Counsel Mike Bodosky and Senior Associate Christine Ryu-Naya. The Firm’s antitrust team has represented Merck in a number of transactions this year.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 700 lawyers practicing throughout a network of 13 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the technology, energy, and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.